Brief: Pivotal Phase 3 SIERRA Trial Data Showing 100% Bone Marrow Transplant Engraftment
15/06/2021 14:02
June 15 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* PIVOTAL PHASE 3 SIERRA TRIAL DATA SHOWING 100% BONE MARROW
TRANSPLANT ENGRAFTMENT IN PATIENTS TREATED WITH IOMAB-B
PRESENTED AT THE 2021 VIRTUAL SNMMI CONFERENCE
* ACTINIUM PHARMA- PERSONALIZED IOMAB-B THERAPY ENABLES
TARGETED
DELIVERY OF RADIATION TO BONE MARROW ENABLING MYELOABLATION IN A
WELL-TOLERATED MANNER
Source text for Eikon: ID:nPn2sRcnXa
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities